Vistagen Therapeutics (VTGN) EBITDA (2011 - 2026)

Vistagen Therapeutics has disclosed EBITDA across 15 years of filings, most recently posting -$13.3 million for Q2 2026.

• In Q2 2026, EBITDA rose 15.54% year-over-year to -$13.3 million; the TTM figure through Jun 2026 stood at -$69.7 million (down 16.8% YoY), while the FY2026 annual figure was -$72.1 million, down 28.86% from the prior year.
• EBITDA came in at -$13.3 million for Q2 2026 at Vistagen Therapeutics, up from -$16.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$6.8 million in Q3 2023 to a low of -$20.1 million in Q3 2025.
• Average EBITDA over 5 years is -$13.9 million, with a median of -$14.4 million recorded in 2024.
• Year-over-year, EBITDA slumped 168.42% in 2022 and surged 64.61% in 2023.
• Over 5 years, EBITDA stood at -$9.8 million in 2022, then grew by 19.28% to -$7.9 million in 2023, then plunged by 91.78% to -$15.1 million in 2024, then dropped by 29.27% to -$19.5 million in 2025, then jumped by 31.71% to -$13.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$13.3 million in Q2 2026, -$16.7 million in Q1 2026, and -$19.5 million in Q4 2025.